Skip to main content

Advertisement

Sections

Page 1 of 39

  1. Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomi...

    Authors: Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:309

    Content type: Research article

    Published on:

  2. Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events.

    Authors: J. Yang, S. M. Lagana, Y. M. Saenger and R. D. Carvajal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:310

    Content type: Case report

    Published on:

  3. Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the p...

    Authors: Daniela Massi, Eliana Rulli, Mara Cossa, Barbara Valeri, Monica Rodolfo, Barbara Merelli, Francesco De Logu, Romina Nassini, Michele Del Vecchio, Lorenza Di Guardo, Roberta De Penni, Michele Guida, Vanna Chiarion Sileni, Anna Maria Di Giacomo, Marco Tucci, Marcella Occelli…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:308

    Content type: Research article

    Published on:

  4. We previously showed that the bacterial lipopeptide Pam3Cys-Ser-Ser, meanwhile established as a toll-like receptor (TLR) 1/2 ligand, acts as a strong adjuvant for the induction of virus specific CD8+ T cells in m...

    Authors: Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:307

    Content type: Research article

    Published on:

  5. The PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with IFN-g signaling. To characterize other factors regulating PD-L1 ...

    Authors: Shuming Chen, George A. Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping Wei, Drew M. Pardoll, Fan Pan and Suzanne L. Topalian

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:305

    Content type: Research article

    Published on:

  6. Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stim...

    Authors: Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:304

    Content type: Short report

    Published on:

  7. Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These incl...

    Authors: Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer and Bruno Ségui

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:303

    Content type: Commentary

    Published on:

  8. Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-de...

    Authors: Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:302

    Content type: Research article

    Published on:

  9. Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse within 7 years and the disease remains incurable. Adoptive Allo...

    Authors: S. Yado, G. Luboshits, O. Hazan, R. Or and M. A. Firer

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:301

    Content type: Research article

    Published on:

  10. Accumulating studies suggest that targeting epigenetic modifications could improve the efficacy of tumor immunotherapy; however, the mechanisms underlying this phenomenon remain largely unknown. Here, we inves...

    Authors: Gang Xiao, Li-Lian Jin, Chao-Qun Liu, Yong-Chun Wang, Ya-Ming Meng, Zhong-Guo Zhou, Jing Chen, Xing-Juan Yu, Yao-Jun Zhang, Jing Xu and Limin Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:300

    Content type: Research article

    Published on:

  11. Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.

    Authors: Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:299

    Content type: Research article

    Published on:

  12. Immunotherapy, especially immune checkpoint inhibition, has provided powerful tools against cancer. We aimed to detect the expression of common immune checkpoints and evaluate their prognostic values in nasoph...

    Authors: Ya-Qin Wang, Yu Zhang, Wei Jiang, Yu-Pei Chen, Shuo-Yu Xu, Na Liu, Yin Zhao, Li Li, Yuan Lei, Xiao-Hong Hong, Ye-Lin Liang, Jun-Yan Li, Lu-Lu Zhang, Jing-Ping Yun, Ying Sun, Ying-Qin Li…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:298

    Content type: Research article

    Published on:

  13. Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction o...

    Authors: Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi and Matteo Fassan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:297

    Content type: Case report

    Published on:

  14. Adoptive transfer of autologous T-lymphocytes transduced with a high affinity NY-ESO-1-reactive T-cell receptor (NY-ESO-1c259 T-cells) has emerged as a promising therapeutic strategy for patients with refractory ...

    Authors: Jocelyn Joseph, Michael J. Nathenson, Van Anh Trinh, Karan Malik, Erica Nowell, Kristen Carter, Shiao-Pei Weathers, George D. Demetri, Dejka Araujo and Anthony P. Conley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:296

    Content type: Case report

    Published on:

  15. While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of pat...

    Authors: Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:295

    Content type: Research article

    Published on:

  16. The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL nu...

    Authors: Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff and Svetlana Hamm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:294

    Content type: Research article

    Published on:

  17. The most common metastatic lesions of prostate cancer are in bone and can be classified into three distinct pathology subtypes: lytic, blastic, and an indeterminate mixture of both. We investigated a cohort of...

    Authors: Claire L. Ihle, Meredith D. Provera, Desiree M. Straign, E. Erin Smith, Susan M. Edgerton, Adrie Van Bokhoven, M. Scott Lucia and Philip Owens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:293

    Content type: Short report

    Published on:

  18. Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically act...

    Authors: Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:292

    Content type: Research article

    Published on:

  19. The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in applicati...

    Authors: Catherine T. Le and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:291

    Content type: Commentary

    Published on:

  20. The peculiar multiple myeloma microenvironment, characterized by up-regulated levels of several inflammatory chemokines, including the CXCR3 receptor ligands CXCL9 and CXCL10, limits NK cell positioning into t...

    Authors: Valentina Bonanni, Fabrizio Antonangeli, Angela Santoni and Giovanni Bernardini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:290

    Content type: Research article

    Published on:

  21. The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce.

    Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri and Quoc-Dien Trinh

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:289

    Content type: Research article

    Published on:

  22. The tumor microenvironment (TME) combines features of regulatory cytokines and immune cell populations to evade the recognition by the immune system. Myeloid-derived suppressor cells (MDSC) comprise population...

    Authors: Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr and Peter Duewell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:288

    Content type: Research article

    Published on:

  23. Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy...

    Authors: David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi and Mark Bower

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:287

    Content type: Commentary

    Published on:

  24. Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immun...

    Authors: Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang and Jia He

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:286

    Content type: Research article

    Published on:

  25. Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced a...

    Authors: Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent and Breelyn A. Wilky

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:285

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:213

  26. Affinity-optimized T cell receptor (TCR)-engineered lymphocytes targeting tumor antigens can mediate potent antitumor responses in cancer patients, but also bear substantial risks for off-target toxicities. Mo...

    Authors: Minh Ngoc Duong, Efe Erdes, Michael Hebeisen and Nathalie Rufer

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:284

    Content type: Research article

    Published on:

  27. Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in a...

    Authors: Florence Baettig, Tatjana Vlajnic, Marcus Vetter, Katharina Glatz, Jürgen Hench, Stephan Frank, Michel Bihl, Roberto Lopez, Michael Dobbie, Viola Heinzelmann-Schwarz and Céline Montavon

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:281

    Content type: Case report

    Published on:

  28. The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required.

    Authors: Gareth D. Healey, Belen Pan-Castillo, Jezabel Garcia-Parra, Julia Davies, Shaun Roberts, Eilir Jones, Kalyan Dhar, Sarika Nandanan, Nasima Tofazzal, Luke Piggott, Richard Clarkson, Gillian Seaton, Asa Frostell, Tim Fagge, Colin McKee, Lavinia Margarit…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:280

    Content type: Research article

    Published on:

  29. The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita. In particular, it remains unexplored how driver mutations ...

    Authors: O. I. Isaeva, G. V. Sharonov, E. O. Serebrovskaya, M. A. Turchaninova, A. R. Zaretsky, M. Shugay and D. M. Chudakov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:279

    Content type: Research article

    Published on:

  30. The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, mos...

    Authors: Andrew A. Davis and Vaibhav G. Patel

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:278

    Content type: Short report

    Published on:

  31. Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus s...

    Authors: Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:277

    Content type: Research article

    Published on:

  32. Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794),...

    Authors: Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Nunez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren A. Chow…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:276

    Content type: Research article

    Published on:

  33. Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN ...

    Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:275

    Content type: Research article

    Published on:

  34. Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells...

    Authors: Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:274

    Content type: Case report

    Published on:

  35. Following publication of the original article [1], the author reported that the current funding section “Kidney Cancer Association Young Investigator Grant provided funding for this project” should be replaced...

    Authors: Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q. Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A. Chan, Robert Uzzo, A. Ari Hakimi, Guru Sonpavde and Elizabeth Plimack

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:273

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:139

  36. Diffuse large B-cell lymphoma (DLBCL) harbors somatic hypermutation (SHM) in the immunoglobulin heavy chain and light chain variable region genes, IGHV and IGK/LV. Recent studies have revealed that IGV SHM cre...

    Authors: Zijun Y. Xu-Monette, Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, Thomas Snyder, Ganiraju C. Manyam, Xiaohong Tan, Hongwei Zhang, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, Govind Bhagat, Wayne Tam…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:272

    Content type: Research article

    Published on:

  37. Chimeric antigen receptor-modified (CAR) T-cell immunotherapy is a novel promising therapy for treatment of B-cell malignancy. Cytokine release syndrome (CRS) and infection are the most common adverse events d...

    Authors: Hui Luo, Na Wang, Liang Huang, Xiaoxi Zhou, Jin Jin, Chunrei Li, Di Wang, Bin Xu, Jinhuan Xu, Lijun Jiang, Jue Wang, Yang Cao, Yi Xiao, Qian Zhang, Xia Mao, Songya Liu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:271

    Content type: Research article

    Published on:

  38. Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, an...

    Authors: Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse and Kun Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:270

    Content type: Research article

    Published on:

  39. Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmu...

    Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:269

    Content type: Research article

    Published on:

  40. The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive...

    Authors: Hyung Soon Park, Woo Sun Kwon, Sejung Park, Eunji Jo, So Jung Lim, Choong-kun Lee, Jii Bum Lee, Minkyu Jung, Hyo Song Kim, Seung-Hoon Beom, Jun Yong Park, Tae Soo Kim, Hyun Cheol Chung and Sun Young Rha

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:268

    Content type: Research article

    Published on:

  41. Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the p...

    Authors: Bridget P. Keenan, Lawrence Fong and Robin K. Kelley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:267

    Content type: Review

    Published on:

  42. Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related...

    Authors: Saade Anastasia, Mansuet-Lupo Audrey, Arrondeau Jennifer, Thibault Constance, Mirabel Mariana, Goldwasser François, Oudard Stéphane and Weiss Laurence

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:266

    Content type: Case report

    Published on:

  43. The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast canc...

    Authors: Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:265

    Content type: Short report

    Published on:

  44. Immune checkpoint inhibitors (ICIs) have achieved impressive success in different cancer types, yet responses vary and predictive biomarkers are urgently needed. Growing evidence points to a link between DNA m...

    Authors: Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:264

    Content type: Research article

    Published on:

  45. The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now ...

    Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg and Eric Vivier

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:263

    Content type: Review

    Published on:

  46. Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs a...

    Authors: Catherine A. Gao, Urs M. Weber, Aldo J. Peixoto and Sarah A. Weiss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:262

    Content type: Case report

    Published on:

  47. Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rate...

    Authors: Kamila Hladíková, Vladimír Koucký, Jan Bouček, Jan Laco, Marek Grega, Miroslav Hodek, Michal Zábrodský, Milan Vošmik, Kateřina Rozkošová, Hana Vošmiková, Petr Čelakovský, Viktor Chrobok, Aleš Ryška, Radek Špíšek and Anna Fialová

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:261

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement